New Jersey is currently home to 1661 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Recruiting
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
04/09/2025
Locations: The John Theruer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Recruiting
This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Jersey Shore University Medical Center/Meridian Hematology & Oncology, Neptune, New Jersey
Conditions: NSCLC
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Recruiting
The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estrogen receptor-low breast cancer (ER-low BC), and whether these study treatments work as well as standard chemotherapy with carboplatin, paclitaxel, capecitabine, or eribulin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: Metastatic Breast Cancer
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Recruiting
The purpose of this study is to find out whether isatuximab is an effective treatment for people who developed immune cytopenias/ICs after allogeneic hematopoietic cell transplant/allo-HCT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: Blood Cancer, Refractory Immune Cytopenias
SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial
Recruiting
To establish the safety and effectiveness of the SEAL™ Saccular Endovascular Aneurysm Lattice system for the treatment of saccular intracranial aneurysms. The data from this study will be used to support a premarket approval (PMA) submission.
Gender:
ALL
Ages:
Between 22 years and 80 years
Trial Updated:
04/09/2025
Locations: The Cooper Health System, Camden, New Jersey
Conditions: Intracranial Aneurysm
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
Recruiting
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/09/2025
Locations: Center for Emotional Fitness Site, Cherry Hill, New Jersey
Conditions: Generalized Anxiety Disorder
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Recruiting
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Hackensack Meridian John Theurer Cancer Center, Hackensack, New Jersey
Conditions: Relapsed/Refractory Multiple Myeloma
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study
Recruiting
The purpose of this trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associated hepatitis (sAH).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/09/2025
Locations: Rutgers-New Jersey Medical School, Newark, New Jersey
Conditions: Alcohol Associated Hepatitis
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
Recruiting
To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle, for treatment of advanced urothelial and non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Atlantic Health System / Morristown Medical Center, Morristown, New Jersey
Conditions: Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Recruiting
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Oncology Clinical Research Referral Office, Hackensack, New Jersey
Conditions: Low Risk Myelodysplastic Syndromes
Smartphones for Opiate Addiction Recovery
Recruiting
Treatments for opioid addiction exist, but effectiveness is compromised when subjects use illicit opiates during treatment. Reuse rates during treatment can be high, and reducing illicit opiate use during treatment has thus recently become a major NIDA policy goal. The 5-minute battery indicates the numerical probability that a patient will reuse illicit opiates within the next 7-10 days.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/09/2025
Locations: Rutgers University, Piscataway, New Jersey
Conditions: Opioid-use Disorder
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
Recruiting
This study will test whether the combination of radiation and Dostarlimab is an effective treatment for women with MMR-D/MSI-H endometrial cancer who have recently undergone surgery.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activites), Basking Ridge, New Jersey
Conditions: Endometrial Cancer